Pangea's Amino forms collab with U of A scientists

Executive Summary

• Pangea Natural Foods Inc.'s wholly owned subsidiary, Amino Innovations, has entered into a strategic scientific collaboration with University of Alberta scientists Dr. Neal Davies and Dr. Raimar Loebenberg.
• The partnership aims to accelerate the research, validation, and development of advanced non-injectable peptide delivery systems for consumer wellness applications.
• The collaboration leverages the University of Alberta's Drug Development and Innovation Centre (DDIC) facilities to conduct in vitro, ex vivo, and in silico studies on peptide absorption, bioavailability, and stability.

Key Details

• Parties Involved: Amino Innovations (subsidiary of Pangea Natural Foods Inc.) and Dr. Neal Davies and Dr. Raimar Loebenberg (senior professors, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta).
• Agreement Structure: Research services agreement providing formulation and validation expertise.
• Facilities: Access to the University's Drug Development and Innovation Centre (DDIC), including state-of-the-art facilities, personnel, and pharmaceutical testing platforms.
• Research Scope:
  • Establishing benchmarks for precision peptide delivery across oral, dermal, and topical formulations.
  • Conducting in vitro, ex vivo, and in silico studies to quantify absorption, bioavailability, and stability.
  • Testing select peptides including BPC-157, GHK-Cu, and KPV.
  • Utilizing natural permeation enhancers such as Tremella fuciformis (Snow Mushroom) and DMSO.
• Key Research Areas:
  • Pharmacokinetic (PK) and pharmacodynamic (PD) modelling to optimize formulation parameters and delivery profiles.
  • Permeation and dissolution testing using skin and tissue-based membrane models.
  • Formulation refinement using natural excipients and botanical actives for enhanced bioavailability.
  • Stability and analytical testing to confirm product integrity and longevity.
• Strategic Goals: Strengthen intellectual property portfolio, enhance regulatory credibility, and accelerate new product development in nutraceutical and cosmeceutical markets.

Notable Quotes

• Dr. Neal Davies and Dr. Raimar Loebenberg: "We are thrilled to work with Amino Innovations, a company that is focused on evidence-based, non-injectable natural peptide innovation. Our expertise in biopharmaceutics, formulation science and translational research will help bring forward validated peptide technologies with measurable impact in wellness and health science."
• Justin Kirkland, Chief Scientific Officer and Co-founder of Amino Innovations: "This partnership gives us access to leading research expertise and infrastructure. By generating pharmacokinetic and permeability data on key peptide actives, we are creating a level of scientific transparency within the wellness industry."
• Pratap Sandhu, Chief Executive Officer of Pangea: "We are excited to support Amino Innovations as it continues to lead in science driven wellness innovation. This partnership reinforces our commitment to developing credible, research-backed products that strengthen scientific integrity and drive long-term growth."